Home Newsfeeds HC Wainwright & Co. Downgrades Neoleukin Therapeutics to Neutral

HC Wainwright & Co. Downgrades Neoleukin Therapeutics to Neutral

HC Wainwright & Co. analyst Robert Burns downgrades Neoleukin Therapeutics (NASDAQ:NLTX) from Buy to Neutral.

byBenzinga Newsdesk

November 16, 2022

1 minute read

HC Wainwright & Co. analyst Robert Burns downgrades Neoleukin Therapeutics (NASDAQ:NLTX) from Buy to Neutral.

Legal
News

Genius Group Settles Litigation With Alto Opportunity Master Fund, SPC, Ayrton Capital, LLC And Waqas Khatri

By Happy Mohamed

March 29, 9:48 AM

Genius Group Limited (NYSE:GNS) ("Genius Group" or the "Company"), a leading entrepreneur edtech and education group, today announced it reached an amicable settlement with Alto Opportunity

GNS

Avidity Biosciences Announces Topline Data From AOC 1001 Phase 1/2 MARINA Trial Demonstrating Functional Improvement, Disease Modification And Favorable Safety And Tolerability Profile In People Living With Myotonic Dystrophy Type 1

By Benzinga Newsdesk

April 27, 3:43 PM

Topline data presented at AAN annual meeting showed AOC 1001 achieved directional improvements in multiple functional endpoint assessments - myotonia (vHOT), measures of strength (total QMT) and mobility (10mWRT, Timed

RNA

Economic Alarm Bells Ring: New York Fed’s 12-Month Recession Probability Soars To Levels Unseen Since 1982

By Piero Cingari

April 19, 11:34 AM

The likelihood of a recession in the United States within the next year has risen to almost 58%, the highest level since August 1982, according to the New York Federal Reserve.

BIL